Loading organizations...
Based in Coventry, England, CryoLogyx develops ready-to-use, cryopreserved cell products that are pre-plated and optimized for immediate assay applications in biotechnology research. The company utilizes its proprietary Cryoshield technology to maintain cell viability and function post-thaw, eliminating routine cell culture requirements for pharmaceutical researchers working across drug discovery, toxicology testing, diagnostics, and cell therapy. Spun out from the University of Warwick in 2020, the enterprise was established by co-founders Tom Congdon and Matt Gibson to support advanced in vitro studies. The business has successfully raised approximately $1.04 million in total funding to date, which includes a recent £500,000 seed round to scale production and expand operations throughout the United Kingdom and Europe. CryoLogyx is currently backed by prominent institutional and private angel investors, including the Wider Oxford Technology Angel Network, Oxford Technology Management, and Innovate UK.
CryoLogyx has raised $640K across 1 funding round.
CryoLogyx has raised $640K in total across 1 funding round.
CryoLogyx has raised $640K across 1 funding round. Most recently, it raised $640K Seed in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2024 | $640K Seed | — | Oxford Technology Management | Announced |
CryoLogyx has raised $640K in total across 1 funding round.
CryoLogyx's investors include Oxford Technology Management.
